At Alector, we are on a mission to slow the progression of neurodegenerative diseases and one day prevent their occurrence.
We are a clinical stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. We are advancing a portfolio of programs built on insights into human genetics, neuroscience, and protein engineering, and increasingly leverage Alector Brain Carrier (ABC), our proprietary blood-brain barrier technology platform designed to deliver antibodies, enzymes, and siRNA broadly throughout the brain.
Today, our pipeline spans partnered and wholly owned programs and we are advancing these next-generation therapeutics through development with the goal of changing the course of devasting neurodegenerative disorders for patients and their families worldwide.
Minimum 15 minutes delayed. Source: LSEG